Johnson & Johnson’s early trials showed:
Efficacy rating: Clinical trials showed that a single dose of the vaccine had an efficacy rate of up to 72 percent (for a time). This means it has a 72% chance of decreasing severe symptoms in the recipient.
For example, a vaccine that's 90 percent effective at preventing illness doesn't mean 10 percent of people who received it will get sick; rather, it means people who got the shot were 90 percent less likely to get sick, compared with people who received a placebo.
The effectiveness varied when researchers tested the vaccine in other countries, where variants of the coronavirus are circulating. In Latin America the vaccine was found to be 66 percent effective. In studies in South Africa effectiveness was lower at 64 percent.
It did prevent 100 percent of hospitalizations and deaths related to Covid-19 for 28 days. Meaning that no one who got the Johnson & Johnson shot was hospitalized or died of Covid-19 during the study's follow-up period of 28 days after vaccination.
Dosing: It's a one-shot process. It's also less fragile than the mRNA vaccines and doesn't require the deep freeze temperatures the others do.
How it works:
Viral vector therapy.